Friday, August 30, 2019 5:08:10 PM
To be a successful investor one needs to be AHEAD of the CURVE AND still in that upcoming environment still be ON the rails!
The above takes many skillsets and few can grapple with in a lifetime given the ultra dynamics of the world we live in: ie Global Warming/Climate Change
Re Crop Yields; Islands disappearing; cities/homes under water etc etc.
Specifically it all relates to understanding how each investment may avoid the above potential exposureS and how each is strategically positioned to withstand the impending onslaughts. Some may need a back up plan. Clearly that’s what supposedly why CEO’s get paid multiple scores above average Corp employees!
Taking BOTH a bottom’s up analysis as well as a top down analysis is the optimal
One clearly needs to understand as it relates to ANY company one cited:
Will they be #1 or # 2 in their respective fields and IF they are not currently what do they need to get to topple those incumbents?
Will consumers still be buying in that environment?
Is the technology far superior?
Where are each company in terms of the products life cycle: I stated two years ago in many posts the
Saturation of Smartphones and Apple’s tough slough in China
LOTS of spadework
Fortunately AMRN’s Vascepa is well positioned as there is an INELASTIC demand for their proprietary compound which I discovered on my own four years ago in surfing thru for the first and only time the FDA’s database that convinced me that Vascepa is a NCE: more than doubled up at ~$1!
DIFFERENT STROKES FOR DIFFERENT FOLKS
The above takes many skillsets and few can grapple with in a lifetime given the ultra dynamics of the world we live in: ie Global Warming/Climate Change
Re Crop Yields; Islands disappearing; cities/homes under water etc etc.
Specifically it all relates to understanding how each investment may avoid the above potential exposureS and how each is strategically positioned to withstand the impending onslaughts. Some may need a back up plan. Clearly that’s what supposedly why CEO’s get paid multiple scores above average Corp employees!
Taking BOTH a bottom’s up analysis as well as a top down analysis is the optimal
One clearly needs to understand as it relates to ANY company one cited:
Will they be #1 or # 2 in their respective fields and IF they are not currently what do they need to get to topple those incumbents?
Will consumers still be buying in that environment?
Is the technology far superior?
Where are each company in terms of the products life cycle: I stated two years ago in many posts the
Saturation of Smartphones and Apple’s tough slough in China
LOTS of spadework
Fortunately AMRN’s Vascepa is well positioned as there is an INELASTIC demand for their proprietary compound which I discovered on my own four years ago in surfing thru for the first and only time the FDA’s database that convinced me that Vascepa is a NCE: more than doubled up at ~$1!
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
